The IMPETUS Cancer Trial. A Technology Delivered Physical Activity Intervention in Cancer (IMPETUS)

July 23, 2018 updated by: Ciaran Haberlin, University of Dublin, Trinity College

Investigating the Feasibility and Acceptability of a Technology Delivered Physical Activity (PA) Intervention in Cancer: The IMPETUS Cancer Trial. (IMproving Physical Activity and Exercise With Technology Use in Cancer Survivors)

Participants will take part in a 12 week intervention, with at least one follow up at 24 +/- 2 weeks. Each participant will be provided with support, motivation and professional guidance about improving physical activity (PA) levels and will be given a commercially available PA tracker. The PA tracker will also include a smartphone or web-based application, where participants can upload their exercise performed each day, and keep up to date with their goals using their smartphone or by logging on to their computer. The aim of the study is to find out how useful and effective technology with support from a healthcare professional is in helping cancer survivors to become more physically active.

This study will measure objective PA levels of the participants at the start of the study and at the end. The acceptability of using this intervention to promote PA in cancer survivors will also be investigated.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

The overall aim is to determine the feasibility of a specific PA intervention, combining technology and professional input, in the cancer survivor population.

Study Design: A single arm feasibility trial of a PA intervention using technology and behavioural change theories as tools to achieve increased PA. Participants in the study will receive 12 weeks of the intervention. Outcomes will be measured at baseline, 12 weeks and 24 weeks (+/- 2 weeks) post baseline.

Patient recruitment: Participants will be recruited from those attending the St. James' Hospital oncology and haematology services. Study personnel will provide further information to these patients and assess them for eligibility. Informed consent will be gained from each participant.

Sample size: Proposed sample size is 60 (based on Sim and Lewis, 2012 recommendations) and allowing for 20% drop-out.

Intervention: This study will use the commercially available 'Fitbit' wearable technology with its paired smartphone application. PA goals will be prescribed by a qualified, chartered physiotherapist using the American Cancer Society (ACS) guidelines (Doyle et al 2006). Participants will use the Fitbit and its paired application for 12 weeks. The Fitbit device is a tool for motivation and monitoring of PA behaviours in this intervention.

This study will also use evidence-based psychological behavioural change theory. Behavioural change techniques include 'self-monitoring of behaviour', 'goal-setting', 'feedback on behaviour' and 'information about health consequences'.

Procedures: This study includes time-points at baseline, 12 weeks (Intervention end) and 24 weeks post baseline (+/- 2 weeks (Follow-up).

Pre-intervention:Consent and PA measurement

  • Consent: Study personnel meets potential participants at their outpatient appointment. The agreement of the patient's consultant to exercise has been obtained before the patient information leaflet (PIL) is provided. The researcher explains the study and gives the potential participant a consent form and a patient information leaflet and a verbal explanation of the study.
  • Initial PA measurement: Participants who consent are given an Actigraph PA monitor which they will be instructed to wear for 7 days to measure their baseline physical activity levels. Participants who wish to consider the study can take the PIL home, post it back, and receive the Actigraph by post.

Baseline Session:

Participants attend

  • 1) An educational session, delivered by the lead researcher, a chartered physiotherapist. This is a group information session on PA following cancer treatment.
  • 2) Educational session to introduce the technological component to the participants and instruct them in use and upload of Fitbit data to allow monitoring by researcher(s).
  • 3) Measurement of height, weight, BMI and body composition and 6 minute walk test During intervention. (week 1-12)
  • Participants wear Fitbit and upload data for self-monitoring and monitoring by chartered physiotherapist researcher.
  • Participants receive scheduled structured telephone calls, giving them feedback on their achievement of goals and reminders about uploading data as follows; 2 calls each week till week 4, 1 call a week between week 4 and 8 and 2 calls, 2 weeks apart between week 8 and week 12.

After intervention ends (12 weeks):

  • Measurement of height, weight, BMI and body composition and 6 minute walk test

  • Participants wear Actigraph x 7 days

    12 weeks after end of intervention:

  • Measurement of height, weight, BMI and body composition and 6 minute walk test
  • Participants wear Actigraph x 7 days

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Ireland
      • Dublin, Ireland
        • St. James's Hospital Dublin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Agreement of the participant's cancer clinician that he/she can participate, including medical clearance to exercise
  • Aged >18 years
  • Completed chemotherapy or radiotherapy with curative intent within the preceding 3 years. Patients may have had chemotherapy or radiotherapy as the sole treatment for cancer, but not surgery alone. Patients who are still on adjuvant hormone therapy and/or adjuvant Her2-directed therapy are eligible (with physician agreement as above).
  • Able to understand English
  • Owns or has access to a device which is compatible with the Fitbit app i.e. smartphone, tablet or computer.

Exclusion Criteria:

  • Diagnosis of prostate cancer or upper gastro-intestinal cancer.
  • Chronic medical and orthopaedic conditions that would preclude exercise (e.g uncontrolled congestive heart failure or angina, recent MI within 6 months recent Pulmonary embolism within 3 months, breathing difficulties requiring oxygen use or hospitalization, osteoarthritis causing significant mobility issues).
  • Confirmed pregnancy
  • Dementia, cognitive impairment or psychiatric illness that would preclude ability to participate in study.
  • Incomplete haematological recovery after chemotherapy (WCC < 3, Hb < 10 or Platelets < 100).
  • Patients<18 years
  • Evidence of active cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
Participants in this group will receive the intervention. They will receive a Fitbit activity tracker, and will also receive support and goal setting with a view to improving their daily physical activity.
Behavioral: Intervention
A physical activity intervention, delivered remotely using a combination of the Fitbit application and support from a chartered physiotherapist.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Physical Activity (Objective)
Time Frame: Baseline, 12 weeks, 24 weeks
Accelerometry will be used to monitor 7 days of activity at Week 0, Week 12 (+/- 2 weeks) and 24 weeks (+/- 2 weeks) post baseline.
Baseline, 12 weeks, 24 weeks
Evaluation of recruitment capability and resulting sample characteristics
Time Frame: 12 weeks
The number of participants we can recruit will be assessed. This will explore the potential sample size of the randomised control trial.
12 weeks
Data collection procedures and outcome measures
Time Frame: 12 weeks
Procedures to collect data will be assessed for suitability and outcome measures used will be analysed for optimisation of measurement of clinical outcomes
12 weeks
Acceptability and suitability of the intervention and study procedures
Time Frame: 12 weeks
Compliance with daily logging of exercise information and adherence to the intervention duration will be assessed
12 weeks
Use of resources and ability to manage and implement the study and intervention
Time Frame: 12 weeks
The ability of study personnel and the availability of resources to implement the study will be assessed, demonstrated by successful implementation of the intervention
12 weeks
Preliminary evaluation of participant responses to intervention
Time Frame: 12 weeks
The qualitative outcome in this feasibility study will invite participants' to provide feedback on the intervention's likelihood of being successful. Satisfaction with the technological intervention will be measured using a questionnaire given to participants at study end (12 weeks).
12 weeks
Change in body composition
Time Frame: Baseline, 12 weeks and 24 weeks
This will be measured at baseline, 12 weeks (Intervention end) and 24 weeks post -baseline (Follow-up). This will be measured in percentage body fat.
Baseline, 12 weeks and 24 weeks
Change in self-report PA
Time Frame: Baseline, 12 weeks and 24 weeks
A modified version of the Godin Leisure Time Exercise Questionnaire will be used.
Baseline, 12 weeks and 24 weeks
Change in quality of life
Time Frame: Baseline, 12 weeks and 24 weeks
The FACT-G scale (general) (Cella et al 1993) will be used to assess quality of life.
Baseline, 12 weeks and 24 weeks
Change in aerobic capacity/endurance
Time Frame: Baseline,12 weeks and 24 weeks
This will be measured using the 6MWT (Six minute walk test).
Baseline,12 weeks and 24 weeks
Change in BMI
Time Frame: Baseline, 12 weeks and 24 weeks
This will be measured at baseline, 12 weeks (Intervention end) and 24 weeks post -baseline (Follow-up). This will be measured in kg/m^2.
Baseline, 12 weeks and 24 weeks
Change in Body Weight (kg)
Time Frame: Baseline,12 weeks and 24 weeks
This will be measured at baseline, 12 weeks (Intervention end) and 24 weeks post -baseline (Follow-up). This will be measured in kg.
Baseline,12 weeks and 24 weeks
Change in waist circumference
Time Frame: Baseline,12 weeks and 24 weeks
This will be measured at baseline, 12 weeks (Intervention end) and 24 weeks post -baseline (Follow-up). This will be measured in cm.
Baseline,12 weeks and 24 weeks
Change in quality of life
Time Frame: Baseline,12 weeks and 24 weeks
The physical functional measure of the SF-36 (Brazier et al 1992) will be used to measure quality of life.
Baseline,12 weeks and 24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Dublin, Trinity College

Investigators

  • Principal Investigator: Ciaran Haberlin, BSc(Physiotherapy), University of Dublin, Trinity College

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2017

Primary Completion (Anticipated)

December 1, 2018

Study Completion (Anticipated)

December 1, 2018

Study Registration Dates

First Submitted

December 19, 2016

First Submitted That Met QC Criteria

January 27, 2017

First Posted (Estimate)

January 30, 2017

Study Record Updates

Last Update Posted (Actual)

July 24, 2018

Last Update Submitted That Met QC Criteria

July 23, 2018

Last Verified

July 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IMPETUS-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer, Breast

Clinical Trials on Intervention

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe